The generic drug game is all about volume and low costs—copying brand-name drugs after patents expire to keep meds affordable. Despite fierce competition and price wars, AI is helping streamline development. This quarter, the sector outperformed: overall revenue beat estimates by nearly 5%, with stocks up 3%. Viatris surged with 8.1% revenue growth and an 8.2% stock gain. ANI Pharmaceuticals stunned with 20% revenue growth and a 14% beat, though its stock dipped 7.5%. Amphastar stumbled with flat revenue and missed targets, sending its stock down 22%.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
